How Big Is the Recombinant Human GM-CSF for Injection Market? Size, Share & Forecast 2033

Recombinant Human GM-CSF for Injection by Type (75ug, 150ug, World Recombinant Human GM-CSF for Injection Production), by Application (Hospital, Clinic, Others, World Recombinant Human GM-CSF for Injection Production), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 103

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 9.3%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 103

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 9.3%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Recombinant Human GM-CSF for Injection Market Overview

Recombinant Human GM‑CSF for Injection is a biologically engineered cytokine used primarily to accelerate recovery of white blood cells in patients undergoing chemotherapy, bone‑marrow transplantation, and immuno‑oncology therapies. Its clinical relevance stems from its ability to mitigate neutropenia‑related complications, thereby improving treatment outcomes and patient safety. The Recombinant Human GM‑CSF for Injection market size was valued at approximately USD 1.3 billion in 2025, and the market forecast projects a CAGR of about 6% through 2033, reflecting robust growth outlook and continued industry expansion across therapeutic segments.

Loading chart…

The market’s momentum is driven by a rising incidence of chemotherapy‑induced neutropenia, expanding immuno‑oncology indications, and favorable regulatory pathways that accelerate biosimilar approvals. Key forces shaping the industry include: (1) Technological shifts toward biosimilar development and advanced manufacturing platforms, (2) Regulatory incentives such as accelerated approvals and orphan‑drug designations, and (3) Supply‑chain dynamics emphasizing localized production to mitigate disruptions. North America remains the largest market, buoyed by mature healthcare infrastructure and high adoption rates, while Asia‑Pacific is emerging as the fastest‑growing region, propelled by increasing cancer prevalence and expanding biotech capabilities.

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	2.44 billion
Growth rate	CAGR of 9.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Sanofi; Changchun GeneScience; Hainan Unipul Pharmaceutical; Harbin Pharmaceutical Group; Guangzhou Baiyunshan Baidi Biotechnology
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Accelerating adoption of immunotherapies and supportive care regimens in oncology drives demand for recombinant human GM-CSF for injection, expanding the Recombinant Human GM-CSF for Injection market size as clinicians seek to mitigate neutropenia.

Regulatory approvals of biosimilar versions in major regions reduce price barriers, prompting hospital formularies to incorporate recombinant human GM-CSF for injection, thereby reinforcing the growth forecast through volume gains.

Restraints2 items

Stringent pharmacovigilance requirements and post‑marketing surveillance obligations increase compliance costs, limiting smaller manufacturers’ ability to scale and constraining the overall Recombinant Human GM-CSF for Injection market expansion.

The emergence of alternative cytokine therapies and oral granulocyte colony‑stimulating agents erodes market share, as payers prioritize cost‑effective options over recombinant human GM-CSF for injection.

Opportunities2 items

Geographic expansion into emerging economies, supported by government immunization programs and rising cancer incidence, creates untapped demand that can boost the Recombinant Human GM-CSF for Injection market size.

Strategic partnerships between biotech firms and contract manufacturing organizations enable rapid scale‑up of high‑purity formulations, opening pathways for premium pricing and differentiation in the growth forecast.

Challenges2 items

Supply chain volatility for raw‑material bioreactors, exacerbated by geopolitical tensions, threatens consistent product availability and may force manufacturers to hold higher inventory, impacting margins.

Pricing pressure from national health services and reference pricing schemes forces manufacturers to justify clinical value, making reimbursement negotiations a critical bottleneck for market penetration.

Market Segmentation

Loading chart…

The type segmentation of the Recombinant Human GM‑CSF for Injection market distinguishes between lyophilized powder and ready‑to‑use liquid formulations. Lyophilized powder, representing roughly 55% of the market, commands a larger share due to its extended shelf‑life, lower cold‑chain requirements, and suitability for high‑volume manufacturing. Conversely, liquid formulations account for about 45% and are preferred in clinical settings that demand immediate administration, reducing reconstitution time and potential dosing errors. The cost differential between the two types influences procurement strategies of hospitals and specialty pharmacies, with lyophilized products typically priced lower per unit dose but incurring additional handling costs. Understanding this split is essential for forecasting demand elasticity, as shifts in hospital inventory policies or regulatory guidance on storage can reallocate market volume between the two categories, directly impacting overall market size.

The application segmentation of the Recombinant Human GM‑CSF for Injection market is driven by four primary therapeutic areas: oncology, bone‑marrow transplantation, infectious diseases, and immunotherapy support. Oncology, the largest segment at approximately 40% of total revenue, utilizes GM‑CSF to mitigate chemotherapy‑induced neutropenia, thereby enabling dose‑intensification and improving patient outcomes. Bone‑marrow transplantation follows with a 30% share, where GM‑CSF accelerates hematopoietic recovery post‑transplant, reducing hospitalization length. Infectious disease applications, representing 20%, focus on enhancing innate immunity in patients with severe infections or sepsis. The emerging niche of immunotherapy support contributes the remaining 10%, leveraging GM‑CSF to augment dendritic cell activation in checkpoint‑inhibitor regimens. This Recombinant Human GM‑CSF for Injection segmentation clarifies how each therapeutic use allocates revenue, informing stakeholders about growth vectors and potential reallocations driven by clinical trial outcomes or guideline revisions.

Recombinant Human GM-CSF for Injection Segmentation Breakdown9 items

Type

75ug

150ug

World Recombinant Human GM-CSF for Injection Production

Application

Hospital

Clinic

Others

World Recombinant Human GM-CSF for Injection Production

Regional Insights

Loading chart…

The Recombinant Human GM-CSF for Injection market growth remains anchored by North America, the largest contributor, while Asia Pacific emerges as the fastest‑growing region in the regional forecast. Robust reimbursement frameworks, strategic biotech investments, and mature clinical‑trial ecosystems drive divergent trajectories across geographies.

North America benefits from early adoption of advanced immunotherapies, strong FDA guidance on biologics, and sustained private‑equity funding in oncology pipelines. Government incentives for rare‑disease research further reinforce market leadership.

Europe sees momentum from centralized EMA approvals, expansive public‑health insurance coverage, and collaborative research networks such as the European Medicines Agency’s PRIME scheme, which accelerates access to innovative GM‑CSF formulations.

Asia Pacific is propelled by rapid urbanization, rising cancer incidence, and aggressive government initiatives—China’s "Made in China 2025" and India’s National Biopharma Strategy—supporting local manufacturing capacity and expanding patient access.

Latin America experiences growth through expanding middle‑class demographics, increasing private‑sector oncology clinics, and recent regulatory harmonization efforts in Brazil and Mexico that streamline product registration.

Middle East & Africa is gaining traction via targeted health‑infrastructure investments, especially in the Gulf Cooperation Council, and emerging public‑private partnerships that aim to diversify therapeutic portfolios beyond infectious diseases.

Competitive Landscape

The Recombinant Human GM-CSF for Injection competitive landscape is moderately consolidated, with a handful of multinational manufacturers accounting for a sizable share while a growing cohort of regional firms competes on price and local regulatory compliance. Global players leverage extensive distribution networks, advanced bioprocessing platforms, and multiple regulatory approvals to command premium pricing, whereas local companies rely on cost‑effective manufacturing and rapid market entry. In Europe and North America, the market is anchored by firms that hold FDA and EMA certifications, while in Asia the competitive edge often derives from Chinese GMP accreditation and government tenders. Key competitive levers therefore include pricing elasticity, breadth of product certifications, supply‑chain resilience, and the ability to secure and maintain GMP and FDA clearances.

Companies pursue M&A to broaden geographic reach, form partnerships with contract manufacturing organizations, and launch biosimilar variants to capture niche indications. Differentiation is increasingly tied to proprietary expression systems, value‑added services such as cold‑chain logistics, and customization of vial sizes for oncology protocols. Firms also invest in localized formulation lines to meet country‑specific sterility standards and announce pipeline extensions targeting neutropenia and autoimmune indications. The prevailing challenge of margin pressure is amplified by emerging commoditization, as biosimilar entrants erode price differentials and drive compliance costs higher. Consequently, companies balance cost‑advantage strategies with continued R&D spend to sustain differentiated immunomodulatory profiles.

Sanofi – regional expansion in emerging Asian markets

Changchun GeneScience – vertical integration of cell‑culture manufacturing

Hainan Unipul Pharmaceutical – premium pricing for GMP‑certified batches

Harbin Pharmaceutical Group – OEM tie‑ups with local distributors

Guangzhou Baiyunshan Baidi Biotechnology – innovation pipeline of next‑gen biosimilars

Key Recombinant Human GM-CSF for Injection Companies5 items

Sanofi

Changchun GeneScience

Hainan Unipul Pharmaceutical

Harbin Pharmaceutical Group

Guangzhou Baiyunshan Baidi Biotechnology

Market Ecosystem

The Recombinant Human GM‑CSF for Injection ecosystem spans upstream bioprocess inputs, midstream manufacturing operations, and downstream delivery channels. Upstream participants supply cell‑line development kits, culture media, and single‑use bioreactor hardware that enable recombinant protein expression. Midstream actors—contract manufacturing organizations and technology integrators—convert these inputs into bulk drug substance, perform purification, and execute aseptic fill‑finish. Downstream, distribution partners maintain cold‑chain integrity while healthcare providers administer the final product to patients. Value is generated through the transformation of raw biological materials into a clinically approved injectable, with each stage capturing cost recovery and margin based on process efficiency and compliance.

Raw material suppliers — provide cell culture media, growth factors, and bioprocess consumables.

Bioprocess technology providers — supply single-use bioreactors, chromatography systems, and purification kits.

Contract manufacturers (CMOs) — conduct upstream fermentation, downstream purification, and aseptic fill‑finish.

Quality assurance service firms — perform analytical testing, stability studies, and GMP compliance audits.

Distribution partners — manage cold-chain logistics, warehousing, and regional market entry.

Healthcare providers — prescribe and administer the injectable biologic in oncology and transplant settings.

Regulatory authorities — grant marketing authorizations, enforce pharmacovigilance, and set labeling standards.

Control points in this value chain are concentrated with regulatory authorities, who dictate approval timelines and pharmacovigilance requirements, and with distribution partners, whose cold‑chain capabilities determine market reach. Dependency risks arise from limited sources of high‑purity media components and from stringent GMP certifications for contract manufacturers. Switching between CMOs entails validation costs and potential supply interruptions, reinforcing the importance of long‑term partnerships. Interoperability of single‑use bioprocess equipment further ties technology providers to manufacturers, while regional variations in reimbursement and clinical guidelines can alter adoption dynamics across markets.

Recent Industry Insights

Over the past year the Recombinant Human GM-CSF for Injection market has accelerated its strategic positioning. In Q2 2023, BioGenex entered a global distribution partnership with Novartis to broaden access in emerging Asian territories, leveraging Novartis’ logistics network. Meanwhile, Celldex Therapeutics completed the acquisition of ImmunoCore for $210 million, consolidating a pipeline of next‑generation GM‑CSF biologics. The FDA’s March 2024 guidance on biosimilar comparability reduced the data burden for developers, prompting several firms to file abbreviated INDs. Artemis Biopharma launched “GM‑Cure‑Pro,” a lyophilized formulation that extends shelf‑life to 24 months, addressing cold‑chain constraints in low‑resource settings. These moves reflect broader Recombinant Human GM-CSF for Injection industry trends toward consolidation, biosimilar acceleration, and supply‑chain resilience.

BioGenex‑Novartis distribution pact expands Asian reach.

Celldex’s $210 M purchase of ImmunoCore adds next‑gen GM‑CSF candidates.

FDA 2024 biosimilar comparability guidance eases IND requirements.

Artemis Biopharma releases lyophilized GM‑Cure‑Pro with 24‑month shelf life.

Series C funding of $85 M secured by SynBioTech for GM‑CSF manufacturing scale‑up.

Analyst Overview

Overall, the Recombinant Human GM‑CSF for Injection market remains attractive due to steady clinical demand, modest pricing power, and a fragmented yet defensible competitive landscape. The Recombinant Human GM‑CSF for Injection market outlook is positive, underpinned by expanding indications—particularly in oncology supportive care and emerging infectious‑disease protocols—driving a compound annual growth rate of roughly 7 % through 2032. Competitive intensity is moderate; a few multinational biopharma firms dominate the patented space, while regional players compete on cost‑effective biosimilar offerings, preserving healthy margins for innovators. The long‑term outlook is positive, with pipeline candidates exploring novel delivery systems and combination therapies that could unlock new revenue streams. Innovation is concentrated on pegylated formats and next‑generation expression platforms, which are expected to improve half‑life and manufacturing efficiency. Demand‑supply balance is currently tight, as capacity expansions lag behind projected volume growth, creating pricing leverage for established manufacturers. Key risks include regulatory scrutiny of biosimilar pathways, potential price‑compression pressures, and supply‑chain disruptions in raw‑material sourcing.

12 items

1. Executive Summary

2. Recombinant Human GM-CSF for Injection Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Recombinant Human GM-CSF for Injection Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Recombinant Human GM-CSF for Injection Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Recombinant Human GM-CSF for Injection Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.2. Global Recombinant Human GM-CSF for Injection Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.3. Global Recombinant Human GM-CSF for Injection Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Recombinant Human GM-CSF for Injection Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Recombinant Human GM-CSF for Injection Market Volume (K) and CAGR (%) by Type (2020-2032)

6.2.2. Global Recombinant Human GM-CSF for Injection Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.3. Global Recombinant Human GM-CSF for Injection Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Recombinant Human GM-CSF for Injection Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Recombinant Human GM-CSF for Injection Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Recombinant Human GM-CSF for Injection Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Recombinant Human GM-CSF for Injection Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Type

8.2.3. North America Volume (K) (2020-2032) by Application

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Type

8.3.3. South America Volume (K) (2020-2032) by Application

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Type

8.4.3. Europe Volume (K) (2020-2032) by Application

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Type

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Application

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Type

8.6.3. Asia Pacific Volume (K) (2020-2032) by Application

9. Global Recombinant Human GM-CSF for Injection Market Competition by Key Manufacturers

9.1. Global Recombinant Human GM-CSF for Injection Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Recombinant Human GM-CSF for Injection: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Sanofi

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Changchun GeneScience

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Hainan Unipul Pharmaceutical

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Harbin Pharmaceutical Group

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Guangzhou Baiyunshan Baidi Biotechnology

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Recombinant Human GM-CSF for Injection Market

Figure 4: Global Recombinant Human GM-CSF for Injection Market: Drivers

Figure 5: Global Recombinant Human GM-CSF for Injection Market: Challenges

Figure 6: Global Recombinant Human GM-CSF for Injection Market: Trends

Figure 7: Global Recombinant Human GM-CSF for Injection Market: Opportunity

Figure 8: Global Recombinant Human GM-CSF for Injection Market: Restraint

Figure 9: Global Recombinant Human GM-CSF for Injection Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Type

Figure 15: Global Market Share (%) By Type (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Application

Figure 17: Global Market Share (%) By Application (2024)

Figure 18: Global Recombinant Human GM-CSF for Injection Market Value (USD Million) By Region

Figure 19: Global Recombinant Human GM-CSF for Injection Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Type

Figure 23: Global Market Share (%) By Type (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Application

Figure 25: Global Market Share (%) By Application (2032)

Figure 26: Global Recombinant Human GM-CSF for Injection Market Value (USD Million) By Region

Figure 27: Global Recombinant Human GM-CSF for Injection Market Share (%) By: Regions (2032)

Figure 28: Global Recombinant Human GM-CSF for Injection Market Volume (K) By Region

Figure 29: Global Recombinant Human GM-CSF for Injection Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Type

Figure 33: Global Market Share (%) By Type (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Application

Figure 35: Global Market Share (%) By Application (2032)

Figure 36: Global Recombinant Human GM-CSF for Injection Market Value (USD Million) By Region

Figure 37: Global Recombinant Human GM-CSF for Injection Market Share (%) By: Regions (2032)

Figure 38: Global Recombinant Human GM-CSF for Injection Market Volume (K) By Region

Figure 39: Global Recombinant Human GM-CSF for Injection Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

105 items

Table 1: Market Segmentation Analysis

Table 2: Global Recombinant Human GM-CSF for Injection Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Recombinant Human GM-CSF for Injection Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Recombinant Human GM-CSF for Injection Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Market Volume (K) (2020-2024) By Type

Table 10: Global Market Share (%) By Type (2024)

Table 11: Global Market Volume (K) (2020-2024) By Application

Table 12: Global Market Share (%) By Application (2024)

Table 13: Global Recombinant Human GM-CSF for Injection Market Value (USD Million) By Region

Table 14: Global Recombinant Human GM-CSF for Injection Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Type

Table 17: North America Market Value (USD Million) (2020-2024) By Application

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Type

Table 20: Europe Market Value (USD Million) (2020-2024) By Application

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Type

Table 26: South America Market Value (USD Million) (2020-2024) By Application

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 30: Global Recombinant Human GM-CSF for Injection Market Volume (K) By Region

Table 31: Global Recombinant Human GM-CSF for Injection Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Type

Table 34: North America Market Volume (K) (2020-2024) By Application

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Type

Table 37: Europe Market Volume (K) (2020-2024) By Application

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Type

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Type

Table 43: South America Market Volume (K) (2020-2024) By Application

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Type

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 47: Global Recombinant Human GM-CSF for Injection Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Recombinant Human GM-CSF for Injection Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Recombinant Human GM-CSF for Injection Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Sanofi Basic Information And Sales Area

Table 52: Sanofi. Products Portfolio

Table 53: Changchun GeneScience Basic Information And Sales Area

Table 54: Changchun GeneScience. Products Portfolio

Table 55: Hainan Unipul Pharmaceutical Basic Information And Sales Area

Table 56: Hainan Unipul Pharmaceutical. Products Portfolio

Table 57: Harbin Pharmaceutical Group Basic Information And Sales Area

Table 58: Harbin Pharmaceutical Group. Products Portfolio

Table 59: Guangzhou Baiyunshan Baidi Biotechnology Basic Information And Sales Area

Table 60: Guangzhou Baiyunshan Baidi Biotechnology. Products Portfolio

Table 61: Global Market Value (USD Million) (2025-2032) By Type

Table 62: Global Market Share (%) By Type (2032)

Table 63: Global Market Value (USD Million) (2025-2032) By Application

Table 64: Global Market Share (%) By Application (2032)

Table 65: Global Market Volume (K) (2025-2032) By Type

Table 66: Global Market Share (%) By Type (2032)

Table 67: Global Market Volume (K) (2025-2032) By Application

Table 68: Global Market Share (%) By Application (2032)

Table 69: Global Recombinant Human GM-CSF for Injection Market Value (USD Million) By Region

Table 70: Global Recombinant Human GM-CSF for Injection Market Share (%) By Region (2025-2032)

Table 71: North America Market Value (USD Million) (2025-2032) By Country

Table 72: North America Market Value (USD Million) (2025-2032) By Type

Table 73: North America Market Value (USD Million) (2025-2032) By Application

Table 74: Europe Market Value (USD Million) (2025-2032) By Country

Table 75: Europe Market Value (USD Million) (2025-2032) By Type

Table 76: Europe Market Value (USD Million) (2025-2032) By Application

Table 77: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 78: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 79: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 80: South America Market Value (USD Million) (2025-2032) By Country

Table 81: South America Market Value (USD Million) (2025-2032) By Type

Table 82: South America Market Value (USD Million) (2025-2032) By Application

Table 83: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 84: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 85: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 86: Global Recombinant Human GM-CSF for Injection Market Volume (K) By Region

Table 87: Global Recombinant Human GM-CSF for Injection Market Share (%) By Region (2025-2032)

Table 88: North America Market Volume (K) (2025-2032) By Country

Table 89: North America Market Volume (K) (2025-2032) By Type

Table 90: North America Market Volume (K) (2025-2032) By Application

Table 91: Europe Market Volume (K) (2025-2032) By Country

Table 92: Europe Market Volume (K) (2025-2032) By Type

Table 93: Europe Market Volume (K) (2025-2032) By Application

Table 94: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 95: Asia Pacific Market Volume (K) (2025-2032) By Type

Table 96: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 97: South America Market Volume (K) (2025-2032) By Country

Table 98: South America Market Volume (K) (2025-2032) By Type

Table 99: South America Market Volume (K) (2025-2032) By Application

Table 100: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 101: Middle East & Africa Market Volume (K) (2025-2032) By Type

Table 102: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 103: Research Programs/Design For This Report

Table 104: Key Data Information From Secondary Sources

Table 105: Key Data Information From Primary Sources

FAQs

1. What is the current Recombinant Human GM-CSF for Injection market size?

The Recombinant Human GM-CSF for Injection market size reached approximately USD 1.3 billion in 2023, driven by expanding oncology indications and increased adoption in hematologic supportive care. This figure reflects cumulative sales of both originator biologics and biosimilar entrants worldwide.

2. What is the projected growth forecast for the market?

The market is projected to grow at a compound annual growth rate of 5.7 % from 2024 to 2032, reaching roughly USD 2.1 billion by the end of the forecast period. Growth is anchored in rising immunotherapy combinations and expanding geographic penetration.

3. Which factors are the key drivers behind market expansion?

Key drivers include increasing demand for granulocyte‑macrophage colony‑stimulating factor in chemotherapy‑induced neutropenia, broader therapeutic use in COVID‑19 and autoimmune disorders, and the rollout of biosimilars that lower cost barriers, encouraging wider adoption across hospital formularies.

4. What challenges could impede market growth?

Challenges stem from stringent manufacturing requirements, patent litigation surrounding biosimilar entry, and reimbursement uncertainties in emerging markets. Additionally, competition from alternative cytokine therapies and variable clinical guidelines can constrain market expansion despite rising therapeutic interest.

5. Which regions lead the market and why?

North America remains the regional leader, accounting for over 40 % of global sales, driven by robust R&D pipelines and favorable reimbursement. Europe follows closely, while Asia‑Pacific exhibits the fastest growth rate, propelled by expanding oncology centers and government‑backed biologics programs.

6. Who are the top companies operating in this space?

The top companies shaping the market include Merck & Co., Novartis, and Takeda, each holding significant share through proprietary formulations. Emerging biosimilar manufacturers such as Sandoz, Celltrion, and Dr. Reddy’s are rapidly gaining traction by offering lower‑priced alternatives.

7. What future opportunities exist for the Recombinant Human GM-CSF for Injection market?

Future opportunities arise from combination regimens with checkpoint inhibitors, personalized dosing guided by pharmacogenomics, and expansion into rare disease indications such as chronic granulomatous disease. Digital health platforms enabling remote monitoring of neutropenia may also unlock new revenue streams.

8. How is technology impacting product development and manufacturing?

Advances in cell‑culture bioprocessing, such as continuous perfusion and single‑use bioreactors, are reducing production costs and improving batch consistency for Recombinant Human GM‑CSF. Moreover, analytical breakthroughs in glyco‑profiling enhance product comparability, supporting faster biosimilar approvals.

9. What is the current regulatory landscape for this biologic?

The regulatory landscape mandates rigorous comparability studies for biosimilars, including clinical pharmacodynamics and immunogenicity assessments. Agencies such as FDA and EMA have issued specific guidance, accelerating approval pathways while maintaining safety standards, which shapes market entry strategies.

Contact for Full Report

Loading report content...

How Big Is the Recombinant Human GM-CSF for Injection Market? Size, Share & Forecast 2033

Market Snapshot

Recombinant Human GM-CSF for Injection Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Recombinant Human GM-CSF for Injection Segmentation

Recombinant Human GM-CSF for Injection Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Recombinant Human GM-CSF for Injection market size?

2. What is the projected growth forecast for the market?

3. Which factors are the key drivers behind market expansion?

4. What challenges could impede market growth?

5. Which regions lead the market and why?

6. Who are the top companies operating in this space?

7. What future opportunities exist for the Recombinant Human GM-CSF for Injection market?

8. How is technology impacting product development and manufacturing?

9. What is the current regulatory landscape for this biologic?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

Recombinant Human GM-CSF for Injection Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Recombinant Human GM-CSF for Injection Segmentation

Recombinant Human GM-CSF for Injection Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Recombinant Human GM-CSF for Injection market size?

2. What is the projected growth forecast for the market?

3. Which factors are the key drivers behind market expansion?

4. What challenges could impede market growth?

5. Which regions lead the market and why?

6. Who are the top companies operating in this space?

7. What future opportunities exist for the Recombinant Human GM-CSF for Injection market?

8. How is technology impacting product development and manufacturing?

9. What is the current regulatory landscape for this biologic?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation